Goat Anti-Llama IgG H&L (HRP) (ab112786)
Key features and details
- Goat Anti-Llama IgG H&L (HRP)
- Conjugation: HRP
- Host species: Goat
- Isotype: IgG
- Suitable for: WB, ELISA, ICC, IHC-P
Related conjugates and formulations
製品の概要
-
製品名
Goat Anti-Llama IgG H&L (HRP)
IgG 二次抗体 製品一覧 -
由来種
Goat -
ターゲット生物種
Llama -
特異性
ab112786 reacts specifically with Llama IgG and with light chains common to other Llama immunoglobulins. No antibody was detected against nonimmunoglobulin serum proteins. -
アプリケーション
適用あり: WB, ELISA, ICC, IHC-Pmore details -
標識
HRP
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C. -
バッファー
pH: 6.8
Constituents: 0.2% BSA, 0.05% CMIT/MIT based preservative -
Concentration information loading...
-
精製度
Immunogen affinity purified -
特記事項(精製)
ab112786 was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to HRP. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Related Products
-
Substrate reagent
- TMB ELISA Substrate (Highest Sensitivity) (ab171522)
- TMB ELISA Substrate (High Sensitivity) (ab171523)
- TMB ELISA Substrate (Fast Kinetic Rate) (ab171524)
- TMB ELISA Substrate (Slow Kinetic Rate) (ab171525)
- TMB ELISA Substrate (Slower Kinetic Rate) (ab171526)
- TMB ELISA Substrate (Slowest Kinetic Rate) (ab171527)
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab112786の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/1000 - 1/30000. Colorimetric: 1/1000-1/10000. Chemiluminescent: 1/1000-1/30000.
|
|
ELISA | (1) |
1/10000 - 1/100000.
|
ICC |
1/200 - 1/500.
|
|
IHC-P |
1/200 - 1/500.
|
特記事項 |
---|
WB
1/1000 - 1/30000. Colorimetric: 1/1000-1/10000. Chemiluminescent: 1/1000-1/30000. |
ELISA
1/10000 - 1/100000. |
ICC
1/200 - 1/500. |
IHC-P
1/200 - 1/500. |
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (9)
ab112786 は 9 報の論文で使用されています。
- Liu H et al. Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. Cell Rep Med 4:100918 (2023). PubMed: 36702124
- Südfeld C et al. The nucleolus as a genomic safe harbor for strong gene expression in Nannochloropsis oceanica. Mol Plant 15:340-353 (2022). PubMed: 34775107
- Van Fossen EM et al. Creating a Selective Nanobody Against 3-Nitrotyrosine Containing Proteins. Front Chem 10:835229 (2022). PubMed: 35265586
- Kamel M et al. Non-Invasive Detection of SARS-CoV-2 Antigen in Saliva versus Nasopharyngeal Swabs Using Nanobodies Conjugated Gold Nanoparticles. Trop Med Infect Dis 7:N/A (2022). PubMed: 35736981
- Marino M et al. AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model. EMBO Mol Med 14:e09824 (2022). PubMed: 35352880
- Szurgot I et al. DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. Sci Rep 11:3125 (2021). PubMed: 33542325
- Gavira-O'Neill CE et al. Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research. Curr Protoc Neurosci 94:e107 (2020). PubMed: 33185319
- Ou K et al. A Novel Nanobody Directed against Ovine Myostatin to Enhance Muscle Growth in Mouse. Animals (Basel) 10:N/A (2020). PubMed: 32796682
- Calpe S et al. Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. MAbs 8:678-88 (0). WB . PubMed: 26967714